Glucantime Resistant Cutaneous Leishmaniasis- A Case Report
DOI:
https://doi.org/10.66344/jpad.35.2.2025.2931Keywords:
Leishmania, Glucantime, KashmoreAbstract
Leishmaniasis is a vector-borne disease caused by flagellated protozoans from the genus Leishmania. This disease is prevalent in tropical and subtropical regions and is found across 98 countries in Europe, Africa, Asia, and the America and has become a global health concern. Transmitted through the bite of female sandflies, Leishmania has become endemic in various regions around the world. According to the WHO, it is estimated that there are approximately 700,000 to 1 million new cases of leishmaniasis worldwide each year. Leishmaniasis manifests in three main forms: visceral (the most severe, often fatal without treatment), cutaneous (the most common, typically causing skin ulcers), and mucocutaneous (affecting the mouth, nose, and throat). However, Pakistan has a burden of cutaneous leishmaniasis. Here we report a case of 24 years old male, who presented from district Kashmore of Pakistan with multiple non healing ulcers on exposed body parts particularly suggestive of Cutaneous Leishmaniasis.References
Roatt BM, de Oliveira Cardoso JM, De Brito RC, Coura-Vital W, de Oliveira Aguiar-Soares RD, Reis AB. Recent advances and new strategies on leishmaniasis treatment. Applied Microbiology and Biotechnology. 2020 Nov;104:8965-77.
Mokni M. Leishmanioses cutanées [Cutaneous lei-shmaniasis]. Ann Dermatol Venereol. 2019 Mar; 146(3):232-246. French.
Doi: 10.1016/j.annder.2019.02.002. Epub 2019 Mar 15. PMID: 30879803.
Abadías-Granado I, Diago A, Cerro PA, Palma-Ruiz AM, Gilaberte YJ. Cutaneous and mucocuta-neous leishmaniasis. Actas Dermo-Sifiliográficas (English Edition). 2021 Jul 1;112(7):601-18
Hotez PA (2011) Handful of ‘antipoverty’ vaccines exists for neglected diseases, but the world's poo-rest billion people need more. Health $?? 30: 1080-1087
Syed AR, Aman S, Hussain I, Kazmi SAH. Kash-mor: focus of cutaneous leishmaniasis. J Pak Assoc Dermatol [Internet]. 2017J an.3 [cited 2024Jul.6]; 16(3):147-50. Available from:
https://www.jpad.com.pk/index.php/jpad/article/view/867
Niba Rawlings N, Bailey M, Courtenay O. Leish-maniasis in deployed military populations: A sys-tematic review and meta-analysis. PLOS Neg-lected Tropical Diseases. 2025 Mar 10;19(3): e0012680.
Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous leishmaniasis. The Lancet infectious diseases. 2007 Sep 1;7(9):581-96.
Pradhan S, Schwartz RA, Patil A, Grabbe S, Gol-dust M. Treatment options for leishmaniasis. Cli-nical and experimental dermatology. 2022 Mar 1;47(3):516-21.
Fernández OL, Belew AT, Rosales-Chilama M, Sánchez-Hidalgo A, Colmenares M, Saravia NG, El-Sayed NM. Interplay of human macrophage response and natural resistance of L.(V.) pana-mensis to pentavalent antimony. bioRxiv. 2024 Nov 2:2024-10.
Pali? S, Beijnen JH, Dorlo TP. An update on the clinical pharmacology of miltefosine in the treat-ment of leishmaniasis. International Journal of Antimicrobial Agents. 2022 Jan 1;59(1):106459.
Downloads
Published
How to Cite
Issue
Section
License
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
